Oviya MedSafe in Pharmacovigilance – Constructing Credibility by Communicating Consistently

Dear Well-wishers,

I have no words to express the deep sense of fulfilment I experience today as I sit down to pen the 100th edition (January 2021) of Oviya MedSafe‘s newsletter, a regular writing commitment I made to myself when I logged the first edition in April 2012, barely a month after founding Oviya MedSafe. On this occasion, I trust it is appropriate to share why Oviya MedSafe’s newsletters are felt by our readers to be unique and engaging.

To begin with, it was the beginning that made the critical difference. At a time when organizations were already well-versed in pseudo-personalizing their newsletters, we preferred to admit that what we sent was indeed mass communication and instead expressed our optimism by addressing our readers as our well-wishers, a term which no business mailer could have ever opted to use. Yet, we did customize the content in such a way that, although written for a group, it appeared customized to any reader who had even a remote connection to Pharmacovigilance. It was possible because Oviya MedSafe’s primary focus was to bring conversations about Pharmacovigilance to the mainstream rather than looking at making immediate business benefits, thanks to our unceasing zeal for the subject. We treated all our readers as co-travellers in our quest and adopted a personal letter format as against using attractive visual effects, which resulted in a sense of involvement in them. Of course, we too wanted to and eventually did grow our business as any other company, but we derived our biggest pride by responding to our highest calling of contributing to the advancement of Pharmacovigilance as a discipline, more than anything else.

While talking about Oviya MedSafe’s offerings, our newsletters always made sure that we not only explained our capabilities but also established how our expertise could add value to our clients. Whenever we wrote about specific support required for certain countries/regions or for particular types of clients, we always provided the context in a succinct manner, which in turn helped decision-makers with little Pharmacovigilance experience too to make the right moves. We never hesitated to elucidate our ways of working in Pharmacovigilance, for we had no doubt in our proficiency. Our newsletters made it a point to describe the current industry practices before detailing how Oviya MedSafe was challenging the status quo. We consciously avoided using industry jargon unless they were absolutely necessary to be used and even when we had to use them, we did so only after defining the terms. Our newsletters not only shared our publications with our readers but also induced leading publishing houses across the globe to reach out to us with requests for exclusive articles on Pharmacovigilance which consequently facilitated us to author many more papers. Apart from these, our newsletters served as the main platform on which we announced our achievements and the recognitions showered upon Oviya MedSafe then and there. In short, it would not be an exaggeration to state that our newsletter editions have chronicled Oviya MedSafe’s evolution over the years and could present themselves as chapters in Oviya MedSafe’s autobiography.

I do not think I will be justified if I stop my narrative with the authentic impact our straight from the heart newsletters have created in the external world, as the beneficial effects have been enjoyed by our own ecosystem as well. From the time that Oviya MedSafe was an enthusiastic start-up to today when we are a globally renowned brand in Pharmacovigilance, our newsletters have been a constant source of motivation to our team, assurance to our shareholders, confidence to our clients, awareness to our colleagues in the industry, orientation to pharmaceutical professionals outside the Pharmacovigilance domain, and inspiration for students & aspiring future employees of Oviya MedSafe. At a personal level, our newsletters have helped me at an extraordinary level in disseminating information about the educational / advocacy / knowledge-sharing / training / stakeholder-engagement initiatives in Pharmacovigilance which I undertook as an individual or as part of several professional societies that I am associated with. In fact, I feel our newsletters have gifted me with innumerable like-minded friends who are always ready to march with me for the cause of advancement of Pharmacovigilance.

At this juncture, I am pleased to unravel our Newsletter Archive which contains the links to all of the 99 newsletter editions we released so far. This archive shall be updated on a real-time basis from now onwards. With a profound sense of gratitude, I dedicate this archive to our loyal readership which has grown from about 300 in 2012 to nearly 30000 in 2021. Please click on https://www.oviyamedsafe.com/archive-of-oviya-medsafes-past-newsletters/ to access the archive. It will be my pleasure to hear your feedback, if any, on this milestone.

Longing to connect with you through our February 2021 newsletter,

With thanks & regards,
Dr J Vijay Venkatraman
MBBS, F. Diab., MBA, FPIPA (UK)

Managing Director & CEO,
Oviya MedSafe Pvt Ltd,
Coimbatore, India
Phone: +91-422-2444442

Director,
Oviya MedSafe UK Ltd,
London, UK
Phone: +44-8452-733839

Web: www.oviyamedsafe.com
Mail: info@oviyamedsafe.com
Follow us on: Facebook, LinkedIn & Twitter